Voya Investment Management LLC Sells 2,679 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Voya Investment Management LLC reduced its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 11.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 21,475 shares of the life sciences company’s stock after selling 2,679 shares during the quarter. Voya Investment Management LLC’s holdings in Integra LifeSciences were worth $487,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Capital Research Global Investors lifted its stake in Integra LifeSciences by 7.4% during the fourth quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company’s stock worth $31,765,000 after purchasing an additional 95,944 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Integra LifeSciences by 10.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company’s stock worth $23,759,000 after buying an additional 103,291 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Integra LifeSciences by 5.5% in the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock worth $9,603,000 after buying an additional 22,000 shares in the last quarter. Leeward Investments LLC MA grew its position in Integra LifeSciences by 7.8% during the fourth quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company’s stock valued at $9,197,000 after acquiring an additional 29,402 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Integra LifeSciences during the fourth quarter worth approximately $8,967,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $12.25 on Friday. The business has a 50 day moving average of $18.93 and a 200 day moving average of $21.87. Integra LifeSciences Holdings Co. has a 52 week low of $11.60 and a 52 week high of $32.66. The company has a market cap of $946.31 million, a PE ratio of -136.10, a P/E/G ratio of 0.73 and a beta of 1.27. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same quarter last year, the company posted $0.55 earnings per share. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

IART has been the topic of several recent research reports. Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a report on Friday, April 11th. JMP Securities decreased their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a report on Friday. JPMorgan Chase & Co. dropped their target price on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. Finally, Wells Fargo & Company dropped their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.